Amyotrophic Lateral Sclerosis - Global Market Trajectory & Analytics

Global Amyotrophic Lateral Sclerosis Market to Reach $1.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Amyotrophic Lateral Sclerosis estimated at US$339.2 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 19.2% over the period 2020-2027.



The U.S. Market is Estimated at $100.6 Million, While China is Forecast to Grow at 18.4% CAGR

The Amyotrophic Lateral Sclerosis market in the U.S. is estimated at US$100.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$199.1 Million by the year 2027 trailing a CAGR of 18.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.1% and 16.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR.

Select Competitors (Total 31 Featured):

• AB Science SA
• Apotex, Inc.
• Aquestive
• Biogen, Inc.
• Brainstorm Cell Therapeutics Inc.
• Cytokinetics, Inc.
• F. Hoffmann-La Roche AG
• Genervon Biopharmaceuticals LLC
• Ionis Pharmaceuticals, Inc.
• Kringle Pharma Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neuralstem, Inc.
• Orion Corporation
• Orphazyme A/S
• Sanofi SA
• Treeway BV
• Valeant Pharmaceuticals International, Inc.
• ViroMed Co., Ltd.